1116235-97-2 Usage
Uses
Used in Pharmaceutical Industry:
GSK1838705A is used as a therapeutic agent for targeting cancer cells. Its ability to inhibit IR, IGF1R, and ALK makes it a promising candidate for the treatment of various types of cancer, as these receptors are often dysregulated in cancer cells, contributing to tumor growth and progression.
Used in Research Applications:
GSK1838705A is used as a research tool for studying the roles of IR, IGF1R, and ALK in cellular processes. By inhibiting these receptors, researchers can gain insights into the molecular mechanisms underlying cell growth, proliferation, and survival, as well as identify potential therapeutic targets for cancer treatment.
Used in Drug Development:
GSK1838705A serves as a lead compound in the development of novel drugs targeting IR, IGF1R, and ALK. Its potent inhibitory activity against these receptors can be leveraged to design and synthesize new molecules with improved pharmacological properties, potentially leading to more effective cancer treatments.
Used in Combination Therapy:
GSK1838705A is used in combination with other anticancer agents to enhance the overall therapeutic effect. Its ability to target multiple receptors involved in cancer cell survival and growth makes it a valuable component in combination therapies, potentially increasing the efficacy of treatment and overcoming drug resistance.
Biological Activity
gsk1838705a is a small-molecule kinase inhibitor that inhibits igf-ir and the insulin receptor with ic50s of 2.0 and 1.6 nmol/l, respectively.igf-1r is a transmembrane receptor which is activated by insulin-like growth factor 1 and by a related hormone igf-2. this protein plays important role in the regulation of development. the insulin receptor is also a transmembrane receptor that is activated by insulin, igf-1 and igf2. this receptor is involved in insulin signaling pathway and plays an essential role in the regulation of glucose homeostasis.gsk1838705a obstructs the in vitro expansion of cell lines got from strong and hematologic malignancies, including numerous myeloma and ewing's sarcoma, and hinders the development of human tumor xenografts in vivo. in spite of the inhibitory impact of gsk1838705a on insulin receptor, insignificant effects on glucose homeostasis were seen at efficacious dosages. gsk1838705a represses the anaplastic lymphoma kinase (alk), which drives the distorted development of anaplastic substantial cell lymphomas, some neuroblastomas, and a subset of non–small cell lung growths.gsk1838705a restrains alk, with an ic50 value of 0.5 nm, furthermore, causes complete relapse of alk-ward tumors in vivo at very-endured measurements. gsk1838705a arrives for a promising antitumor agent for helpful use in human growth.
references
[1]. sabbatini p, et al. gsk1838705a inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. mol cancer ther. 2009 oct;8(10):2811-20.
Check Digit Verification of cas no
The CAS Registry Mumber 1116235-97-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,1,6,2,3 and 5 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1116235-97:
(9*1)+(8*1)+(7*1)+(6*6)+(5*2)+(4*3)+(3*5)+(2*9)+(1*7)=122
122 % 10 = 2
So 1116235-97-2 is a valid CAS Registry Number.
1116235-97-2Relevant academic research and scientific papers
2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER
-
Page/Page column 360-362, (2009/04/25)
Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
